Dystrophinopathy

3

Review clinical trials related to Dystrophinopathy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Duchenne Electronic Health Record Study

This study aims to collect retrospective and prospective, long-term data of patients with dystrophinopathy (including Duchenne, Becker, and female carriers) through electronic transfer. At select clinics across the United States, electronic health record (EHR) data from consented patients will be pushed into PPMD's Duchenne Outcomes Research Interchange (the Interchange), where the EHR data can be combined with patient-reported data from The Duchenne Registry. By combining this data in a central hub, we will gain a more complete picture of Duchenne and Becker muscular dystrophy, allowing researchers and clinicians to develop treatments faster and to improve and refine the standards of care for Duchenne and Becker. The ultimate goal is to optimize function, quality of life, and survival of Duchenne and Becker patients. EHR data collected will be fully identifiable retrospective data for core clinical data elements going back ten years (as available) from the date of consent; going back one year for retrospective clinical notes from the date of consent; and prospectively collecting both core clinical data elements and clinical notes. Information collected will align with the FHIR U.S. core data elements, also known as the Common Clinical Data Set. PPMD partnered with Prometheus Research (an IQVIA company), an industry leader in health data informatics, to launch both the EHR Study and the Interchange. All data is stored securely and in accordance with strict industry standards and patient privacy laws. Participation in the EHR data extraction is voluntary, and a patient can withdraw consent at any time.

Participants needed: 2,500
Trial details
Biological sex: AllType: ObservationalSponsor: The Duchenne RegistryUpdated: May 27, 2026Locations: 10Duration: 20 Years
Eligibility criteria

Duchenne or Becker muscular dystrophy or female carrier [+2]

Individuals with other forms of muscular dystrophy [+1]

Status: Not yet recruiting

VirtualPark_Pediatric

The goal of this clinical trial is to assess the effects of a dual-task, multimodal training program on slowing functional motor decline in children and adolescents with neuromuscular disorders. The main questions it aims to answer are: Does Virtual Park slow functional motor decline in children and adolescents with neuromuscular diseases compared with standard therapy? Does Virtual Park contribute to increased engagement and improved neuropsychological function? If there is a comparison group, Researchers will compare dual-task cycling supported by the Virtual Park application to standard therapy to see whether it improves motor and neuropsychological functions and engagement. Participants will undergo two phases: * Phase 1: 3 months of standard therapy; * Phase 2: 3 months of experimental conditions in which patients undergo a rehabilitative intervention with Virtual Park, 3 times a week.

Participants needed: 22
Trial details
Age: 6-18Biological sex: AllType: InterventionalSponsor: Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero AvanzatoUpdated: May 12, 2026Locations: 4
Eligibility criteria

availability of a definitive clinical or molecular genetic diagnosis of a neurom... [+3]

other concomitant genetic diseases; [+3]

Status: Recruiting

The Duchenne Registry

The Duchenne Registry is an online, patient-report registry for individuals with Duchenne and Becker muscular dystrophy and carrier females. The purpose of the Registry is to connect Duchenne and Becker patients with actively recruiting clinical trials and research studies, and to educate patients and families about Duchenne and Becker care and research. At the same time, The Duchenne Registry is a valuable resource for clinicians and researchers in academia and industry, allowing access to de-identified datasets provided by patients and their families-information that is vital to advances in the care and treatment of Duchenne. The Duchenne Registry is a member of the TREAT-NMD Neuromuscular Network.

Participants needed: 10,000
Trial details
Biological sex: AllType: ObservationalSponsor: The Duchenne RegistryUpdated: May 8, 2026Locations: 1Duration: 40 Years
Eligibility criteria

Diagnosis of Duchenne or Becker muscular dystrophy; Manifesting female carriers...

Diagnosis of any other type of muscular dystrophy (including limb-girdle muscula...